AX 0810
Alternative Names: AX-0810Latest Information Update: 15 May 2024
At a glance
- Originator ProQR Therapeutics
- Class Hepatoprotectants; RNA
- Mechanism of Action Sodium-bile acid cotransporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 08 May 2024 Pharmacodynamics data from a preclinical proof of concept trial in Liver disorders released by ProQR Therapeutics
- 03 Apr 2023 Preclinical trials in Liver disorders in Netherlands (Parenteral)
- 29 Mar 2023 ProQR Therapeutics plans clinical development for AX 0810 in late 2024 or early 2025